First Trust SMID Growth Strength ETF (FSGS) Stock Price

32.0463 ▲ +0.0421 (+0.13%)
Open: 32.15 Vol: 564 Day's range: 32.0463 - 32.15 Sep 25, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
FSGS Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 32.22▼ 32.22▼ 32.22▼ 32.21▼ 32.95▼
MA10 32.52▼ 32.52▼ 32.52▼ 32.42▼ 33.07▼
MA20 33.09▼ 33.10▼ 33.12▼ 32.87▼ 32.19▼
MA50 32.23▼ 32.23▼ 32.13▲ 33.01▼ 31.21▲
MA100 31.32▲ 31.36▲ 31.33▲ 32.09▼ N/A    
MA200 30.66▲ 30.32▲ 30.24▲ 31.34▲ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.209▼ -0.210▼ -0.214▼ -0.116▼ -0.064▼
RSI 41.337▼ 41.429▼ 42.790▼ 35.078▼ 49.953▼
STOCH 5.518▼ 5.518▼ 5.438▼ 11.511▼ 60.203    
WILL %R -97.452▼ -97.452▼ -97.990▼ -90.984▼ -57.536    
CCI -76.910     -76.910     -76.150     -126.876▼ -41.923    
Latest Filters Detected On FSGS
▼ MA $FSGS MA(20) Crossed Below MA(50) Set Alert
▼ BREAK $FSGS Price Breaks 30 Days Low Set Alert
▼ BREAK $FSGS Price Breaks 20 Days Low Set Alert
▼ BREAK $FSGS Price Breaks 10 Days Low Set Alert
First Trust SMID Growth Strength ETF News
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI ...
Wednesday, September 23, 2026 04:00 AM
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Travere signals potential for more than $3B in peak annual FILSPARI sales as FSGS launch exceeds expectations
Wednesday, August 05, 2026 02:30 AM
"The second quarter was exceptional." (President, CEO & Director Eric Dube) "This was the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS, and we are very ...
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins
Thursday, February 19, 2026 05:19 PM
Management expects FILSPARI to deliver robust growth as a foundational therapy in IgA nephropathy in 2026, with Peter Heerma expressing confidence in "sustainable growth and long-term leadership in ...
FSGS historical stock data
date open high low close volume
25/09/26 32.15 32.15 32.0463 32.0463 564
24/09/26 31.929 32.0042 31.929 32.0042 243
23/09/26 32.335 32.335 32.0884 32.0884 902
22/09/26 32.70 32.70 32.241 32.3929 2,423
21/09/26 32.56 32.58 32.5352 32.5352 1,115
18/09/26 32.355 32.368 32.355 32.368 210
17/09/26 32.92 32.92 32.5295 32.5534 1,555
16/09/26 32.5471 32.5471 32.5471 32.5471 76
15/09/26 32.6417 32.6417 32.6417 32.6417 87
14/09/26 32.9899 32.99 32.93 32.9894 7,284
Quote Details
52wk Low:28.35
52wk High:34.155
Vol:564
Avg Vol(3m):21.2K
1Y Chng:+6.12%
1M Chng:-6.17%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00